LinKinVax and Inserm Transfert Enter Into an Exclusive Worldwide Licensing Agreement Covering Use of an Innovative Vaccine Platform
Retrieved on:
Thursday, February 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, CEO, UPEC, Entrepreneurship, Immune system, Cell, IMRB, University, MD, VRI, University of Paris-Est Marne-la-Vallée, SOITEC, Technology, Research, Vaccine Research Center, Biomedical Research, HIV, Medicine, Public service, Antigen, Public health, Health, Medical research, Vaccine, Knowledge, Doctor of Philosophy, Severe acute respiratory syndrome coronavirus 2, Industry, CD40, Technology transfer, B cell, National Institute, Chlamydia, Pharmaceutical industry, Inserm, LinKinVax technology, LinKinVax, Inserm Transfert, LINKINVAX TECHNOLOGY, LINKINVAX, INSERM TRANSFERT
LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.
Key Points:
- LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.
- LinKinVax is developing a vaccine platform that directly targets dendritic cells.
- This research has accelerated adaptation of this vaccine platform to several infectious agents, including SARS-CoV-2 with a universal approach to cover multiple variants.
- LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).